SCHEMBL1630272

SCHEMBL1630272

COC(=O)C(N)C1CCCC1

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 2/20 0.45
DPP4 P27487 8/20 0.44
THRB P10828 1/20 0.44
TP53 P04637 1/20 0.44
CA12 O43570 2/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
MMP2 P08253 2/20 0.43
CA9 Q16790 2/20 0.43
ALDH1A1 P00352 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TSHR P16473 1/20 0.41
EPHX1 P07099 1/20 0.40
DPP7 Q9UHL4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12723953 1.00 SLC6A3 (0.45) SLC6A3DPP4THRBTP53CA12
SCHEMBL8254579 1.00 SLC6A3 (0.45) SLC6A3DPP4THRBTP53CA12
SCHEMBL4570295 0.98 DPP4 (0.47) SLC6A3DPP4THRBTP53CA12
SCHEMBL954821 0.98 DPP4 (0.47) SLC6A3DPP4THRBTP53CA12
Hydrochloric Acid SCHEMBL4061487 0.98 SLC6A3 (0.44) SLC6A3DPP4THRBTP53CA12
SCHEMBL24724891 0.98 DPP4 (0.47) SLC6A3DPP4THRBTP53CA12
SCHEMBL8283254 0.98 DPP4 (0.47) SLC6A3DPP4THRBTP53CA12
Hydrochloric Acid SCHEMBL1630271 0.98 SLC6A3 (0.44) SLC6A3DPP4THRBTP53CA12
SCHEMBL22143669 0.98 DPP4 (0.47) SLC6A3DPP4THRBTP53CA12
SCHEMBL2608454 0.98 DPP4 (0.47) SLC6A3DPP4THRBTP53CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117800944-A Pyridine amide derivative, pharmaceutical composition containing same and medical application of pharmaceutical composition 苏州阿尔脉生物科技有限公司 2024-04-02 CN disclosed
EP-2183260-B1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV IDENIX PHARMACEUTICALS INC (US) 2011-06-01 EP disclosed
US-7932240-B2 Phosphadiazine HCV polymerase inhibitors IV IDENIX PHARMACEUTICALS, INC. (US) 2011-04-26 US disclosed
EP-2183260-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV IDENIX Pharmaceuticals, Inc. (US) 2010-05-12 EP disclosed
US-20090081158-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV IDENIX PHARMACEUTICALS, INC. (US) 2009-03-26 US disclosed
WO-2009032180-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV IDENIX PHARMACEUTICALS, INC. (US) 2009-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090081158-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV POLI, ITPA, POLR2H SLC6A3 4321/4885DPP4 317/4885THRB 3215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.